モスネツズマブ(遺伝子組換え)
Mosunetuzumab (Genetical Recombination)
モスネツズマブは,CD20及びCD3ε鎖に対する遺伝子組換え二重特異性モノクローナル抗体であり,抗CD20抗体及び抗CD3ε鎖抗体の相補性決定部はそれぞれマウス抗体に由来し,その他はヒトIgG1に由来する.抗CD20-H鎖の2つのアミノ酸残基が置換(N302G,T371W)され,抗CD3ε-H鎖の4つのアミノ酸残基が置換(N299G,T368S,L370A,Y409V)されている.モスネツズマブは,CHO細胞により産生される.モスネツズマブは,452個のアミノ酸残基からなる抗CD20-H鎖(γ1鎖)1本,213個のアミノ酸残基からなる抗CD20-L鎖(κ鎖)1本,449個のアミノ酸残基からなる抗CD3ε-H鎖(γ1鎖)1本及び219個のアミノ酸残基からなる抗CD3ε-L鎖(κ鎖)1本で構成されるタンパク質である.
Mosunetuzumab is a recombinant bispecific monoclonal antibody against CD20 and CD3ε chain, which is composed of anti-CD20 antibody and anti-CD3ε chain antibody whose complementarity-determining regions are derived from respective mouse antibodies and other regions are derived from human IgG1. In the anti-CD20-H-chain, the amino acid residues are substituted at 2 positions (N302G, T371W). In the anti-CD3ε-H-chain, the amino acid residues are substituted at 4 positions (N299G, T368S, L370A, Y409V). Mosunetuzumab is produced in CHO cells. Mosunetuzumab is a protein composed of an anti-CD20-H-chain (γ1-chain) consisting of 452 amino acid residues, an anti-CD20-L-chain (κ-chain) consisting of 213 amino acid residues, an anti-CD3ε-H-chain (γ1-chain) consisting of 449 amino acid residues, and an anti-CD3ε-L-chain (κ-chain) consisting of 219 amino acid residues.
[1905409-39-3]
|